Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Chronic granulomatous disease (CGD) research: an interview with Dr. Griffin Rodgers, NIDDK director

Chronic granulomatous disease, or CGD, is a diverse group of inherited diseases in which certain cells of the immune system have difficulty forming reactive oxygen compounds, most importantly superoxide radicals. These are used by these white blood cells to kill certain bacteria.

3 Sep 2013

Stem cell researchers receive Early Translational research awards from CIRM

Four prominent researchers from UCLA's Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received Early Translational research awards totaling approximately $13 million from the California Institute for Regenerative Medicine (CIRM) the state stem cell agency. The UCLA researchers received four of the 12 total awards; no other applicant institution received more than one award.

30 Aug 2013

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has introduced a highly specific HER3 rabbit monoclonal antibody (mAb), an important addition for researchers studying HER2-mediated breast, lung and ovarian tumors.

From Cell Signaling Technology 28 Aug 2013

Companion diagnostics: an interview with Trevor Hawkins, SVP, Strategy, Innovation and Business Development for Siemens Healthcare Diagnostics

Companion diagnostics is critical in helping to pave the way for personalized medicine, in which the treatment is adapted and precisely tailored to the patient.

From Siemens Healthineers 27 Aug 2013

HIV-infected people who carry gene face greater risk of contracting cryptococcal disease

HIV-infected people who carry a gene for a specific protein face a 20-fold greater risk of contracting cryptococcal disease, according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.

27 Aug 2013

Powerful new option for treating vasculitis

In a study published in the New England Journal of Medicine, a research consortium that includes the University of Alabama at Birmingham (UAB) has shown that a new drug for vasculitis, a potentially life-threatening auto-immune disease which causes inflammation in blood vessels, is as effective as standard therapy over 18 months.

27 Aug 2013

Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

Laureate Biopharma is pleased to announce its successful collaboration with Dyax Corp. for process development and cGMP production of a new treatment candidate for hereditary angioedema.

26 Aug 2013

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals Inc. announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.

26 Aug 2013

Athera Transfers Annexin A5 Project To Medirista

...

23 Aug 2013

Athera Transfers Annexin A5 Project To Medirista

...

23 Aug 2013

Macrogenics Received $10M Milestone From Servier

...

22 Aug 2013

Adimab Scores Two Deals And Some Milestone Payments

...

22 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

UC Davis Health System develops new screening strategy for lethal stage of TB in Asia

More than 20,000 people in Pakistan are being tested for the potentially deadly stage of tuberculosis using a new strategy developed at UC Davis Health System to effectively detect the disease in children for the first time.

22 Aug 2013

Clinical trial shows type-1 diabetes patients treated with teplizumab exhibit greater response to therapy

Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls.

20 Aug 2013

New antibodies estimate risk of polyps developing into bowel cancer

Polyps in the mucosa of the colon are a common finding during screening colonoscopies. Some sub-groups of polyps are classed as precursors of bowel cancer. Until now, it has not been possible to precisely estimate the risk of these polyps developing into bowel cancer.

19 Aug 2013

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B.

17 Aug 2013

Arrays of nanoscale sensors detect flaws in drugs and help improve production

MIT chemical engineers have discovered that arrays of billions of nanoscale sensors have unique properties that could help pharmaceutical companies produce drugs - especially those based on antibodies - more safely and efficiently.

17 Aug 2013

Omeros announces financial results for second quarter of 2013

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

12 Aug 2013

Antibody News and Research

Further Reading

Chronic granulomatous disease (CGD) research: an interview with Dr. Griffin Rodgers, NIDDK director

Stem cell researchers receive Early Translational research awards from CIRM

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

Companion diagnostics: an interview with Trevor Hawkins, SVP, Strategy, Innovation and Business Development for Siemens Healthcare Diagnostics

HIV-infected people who carry gene face greater risk of contracting cryptococcal disease

Powerful new option for treating vasculitis

Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Athera Transfers Annexin A5 Project To Medirista

Athera Transfers Annexin A5 Project To Medirista

Macrogenics Received $10M Milestone From Servier

Adimab Scores Two Deals And Some Milestone Payments

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

UC Davis Health System develops new screening strategy for lethal stage of TB in Asia

Clinical trial shows type-1 diabetes patients treated with teplizumab exhibit greater response to therapy

New antibodies estimate risk of polyps developing into bowel cancer

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Arrays of nanoscale sensors detect flaws in drugs and help improve production

Omeros announces financial results for second quarter of 2013

Antibodies eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News